i have been monitoring some pharma cos for turnaround and found one such company Novartis which is delivering positive results compared to year earlier , from last year annual negative eps its trailing twelve months eps has risen phenomenally to Rs 21.74 just in two quarters of the current financial year and if this trend continues for remaining two quarter i expect it to close at 35 plus eps, which will be a very good thing for valuations i presume but one thing which i found out was this company inspite being a renowned Multinational with 70 percent promoter holding is not rated by any brokerage houses , so would like to know any good reason for this, so please share your insights to why no coverage on this co yet by any brokerages?
1 Like